Therapeutic and diagnostic methods
AssigneeAlzheimer's Institute of America, Inc.
InventorsTracey C. Fleischer, Daniel M. Cimbora, Jeffrey S. Flick, Andrew D. Gassman, Vijay R. Baichwal, Damon I. Papac
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.
Claims17
A method of treating cancers associated with low level expression of nicotinic acid phosphoribosyltransferase 1 (Naprt1), comprising:
- identifying a cancer associated with a low level of Naprt1 expression;
- and
- administering to a subject in need thereof, a composition comprising a therapeutically effective amount of a compound of Formulae I-IVc or a compound of Tables 1 or 2, or a pharmaceutically acceptable salt thereof.
A method of treating cancers associated with low level expression of nicotinic acid phosphoribosyltransferase 1 (Naprt1), comprising:
- identifying a cancer associated with a low level of Naprt1 expression,
- administering to a subject in need thereof, a composition comprising a therapeutically effective amount of:
- (i) nicotinic acid;
- (ii) a compound of Formulae I-IVc or a compound of Tables 1 or 2, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.